EMANCIPATE versus EXPO: Different results can be explained by differing study designs [2]

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 2, 2008, Pages 152-

  Labenz, Joachim ^a  

^a Ev Jung Stilling Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

CLINICAL STUDY; DEMOGRAPHY; DRUG EFFICACY; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; LETTER; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RELAPSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; RECURRENCE; RESEARCH DESIGN;

EID: 38049148331     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f3a18e     Document Type: Letter

References (5)

1. Goh K-L, Benamouzig R, Sander P, Schwan T. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007; 19:205-211.
2. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, et al. Esomeprazole 20 mg versus pantoprazole 20mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22:803-811.
3. Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 2003; 38:1197-1199.
4. Gillessen A. Balanced perspective essential in erosive esophagitis treatment. Aliment Pharmacol Ther 2005; 22:889-890.
5. Labenz J. Balanced perspective essential in erosive esophagitis treatment; author reply. Aliment Pharmacol Ther 2005; 22:890-891.